17 results about "Essential hypertension" patented technology

Provided herein are methods of treating a patient, such as a human patient, having inflammation or an inflammatory disease or a disease in which inflammation is present, such as cardiovascular or vascular endothelium inflammation, such as pulmonary hypertension, restenosis, essential hypertension, atherosclerosis, stroke, sepsis, or a viral infection, such as a coronavirus infection, SARS-CoV-2. The methods comprise administering to the patient an amount of a compound as described herein effective to treat the patient. NCOA7-activating compounds and compositions also are provided. Also provided is a gene editing method of reducing inflammation or an inflammatory condition in a patient having a C at SNP rs 11154337, comprising editing the C to a G.

The invention relates to application of taurochenodeoxycholic acid in preparation of a medicine for preventing and treating hypertension. The key effect of the taurochenodeoxycholic acid in prevention and treatment of hypertension is found for the first time, that is, the taurochenodeoxycholic acid can significantly enhance the diastolic function of arteriole of a hypertensive patient, so that the effect of reducing blood pressure is achieved. Therefore, the invention provides a new application of taurochenodeoxycholic acid in preparation of the medicine for preventing and treating hypertension, a new medicine for preventing and treating hypertension is provided clinically, and the taurochenodeoxycholic acid has a good clinical application value and a wide application prospect. The taurochenodeoxycholic acid can be prepared into a medicine, a pharmaceutical composition, food, a health care product or a food additive by utilizing the key effect of the taurochenodeoxycholic acid in hypertension diseases, can be used for treating hypertension diseases including primary hypertension and salt-sensitive hypertension, and has important application value.

The application provides a marker for diagnosing primary aldosteronism, a model and application thereof, and combines a univariate analysis and a logistic regression analysis method, analyzes primary aldosteronism samples and primary hypertension samples in a national multicenter cohort, screens out a marker that can be used for predicting whether an individual has primary aldosteronism, and further utilizes a decision tree algorithm to construct a prediction model, realizes intelligent, rapid and simple prediction and diagnosis of primary aldosteronism based on LC-MS / MS technology and the prediction model, and meets clinical requirements.

This application belongs to the field of immunoassay technology, and discloses an aldosterone sandwich antibody mAb5 or its antigen-binding fragment, its preparation method, and its applications. The aldosterone sandwich antibody mAb5 or its antigen-binding fragment includes a light chain variable region (VL) and a heavy chain variable region (VH). The light chain variable region (VL) includes complementarity-determining regions (LCDR1, LCDR2, and LCDR3), whose amino acid sequences are shown in SEQ ID NO. 1-3, respectively. The heavy chain variable region (VH) includes complementarity-determining regions (HCDR1, HCDR2, and HCDR3), whose amino acid sequences are shown in SEQ ID NO. 4-6, respectively. Using the aldosterone sandwich antibody mAb5 of this application to detect aldosterone standard antigens, the detection sensitivity is less than 7 pg / mL. Magnetochemiluminescence immunoassay of clinical samples shows good correlation with clinical results within the sample range of 0-1000 pg / mL, which is of great significance in the diagnosis and treatment of essential hypertension and other aldosterone-related diseases.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for reducing blood pressure and a preparation method thereof. The product provided by the invention is suitable for primary hypertension patients, especially patients who have poor tolerance to chemical antihypertensive drugs and worry about adverse reactions or prefer to traditional Chinese medicine treatment. Patients orally take the traditional Chinese medicine composition according to recommended doses every day, and the effect of reducing blood pressure is achieved through the synergistic effect of all the components in the traditional Chinese medicine composition (for example, the chrysanthemum bud has the effect of clearing heat and calming the liver, the radix puerariae has the effect of clearing and activating the channels and collaterals, the earthworm has the effect of clearing heat and arresting convulsion, the eucommia ulmoides has the effect of tonifying liver and kidney and strengthening muscles and bones, and the radix paeoniae alba has the effect of nourishing blood and liver).

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine formula for treating primary hypertension. The traditional Chinese medicine formula for treating primary hypertension comprises the following components in parts by weight: 10-15 parts of angelica sinensis; 10 to 15 parts of radix rehmanniae; 5-10 parts of Chinese herbaceous peony; 15 to 20 parts of radix puerariae; 5 to 10 parts of fructus gardeniae; 3-7 parts of coptis chinensis; 5-10 parts of radix scutellariae; 10 to 15 parts of hawthorn; 10-15 parts of eucommia ulmoides; 3-6 parts of fritillary bulb; 2-6 parts of radix aucklandiae; 4-9 parts of polygala tenuifolia; 1-4 parts of rhizoma cyperi; 3-7 parts of earthworm; 5-10 parts of radix astragali; 5-10 parts of motherwort herb; 1-2 parts of herba siegesbeckiae; and 1-2 parts of apocynum venetum. The traditional Chinese medicine formula for treating primary hypertension provided by the invention has the effects of treating primary hypertension, Meniere's syndrome, cerebral arteriosclerosis, vertebrobasilar artery insufficiency, nervous tinnitus and neurasthenia; the traditional Chinese medicine composition is remarkable in antihypertensive effect, safe and free of side effects.

The invention belongs to the technical field of medicine and health, and relates to a method for constructing a plateau environment primary hypertension rat model through a low-pressure oxygen cabin, and the method comprises the steps of preparing a DM-SHR rat model, and comprises the following steps of purchasing, feeding, grouping, debugging and detecting. The experimental device is complete in structure and complete in function, can effectively simulate the influence of the plateau environment on the rat hypertension and the physiological pathology of the rat hypertension, ensures the accuracy and repeatability of experimental results, and provides powerful support for research and development and mechanism research of related drugs in the future.

The invention discloses an angiotensin II receptor type 1 immunogenic short peptide and application thereof. The amino acid sequence of the immunogenic short peptide is as shown in SEQ ID No.1: AFHYE. The effective component of the immunogenic vector vaccine is formed by coupling immunogenic oligopeptide and a vector. Immunogenic oligopeptides and a Qbeta carrier are coupled to obtain the vaccine effective component of the angiotensin II receptor type 1 immunogenic peptide fragment. The immunogenic carrier vaccine prepared from the active ingredients is used for antihypertensive treatment of primary hypertension, can be used as a long-acting antihypertensive drug, and is beneficial to improving the treatment compliance of patients with primary hypertension, so that the purpose of effectively controlling blood pressure is achieved.

The invention belongs to the technical field of immunodetection, and discloses an aldosterone sandwich method antibody mAb7 or an antigen binding fragment thereof, and a preparation method and application thereof. The aldosterone sandwich method antibody mAb7 or the antigen binding fragment thereof comprises a light chain variable region VL and a heavy chain variable region VH, the light chain variable region VL comprises complementary determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequences of the light chain variable region VL and the heavy chain variable region VH are respectively shown as SEQ ID NO.1-3, the heavy chain variable region VH comprises complementary determining regions HCDR1, HCDR2 and HCDR3, and the amino acid sequences of the heavy chain variable region VH are respectively shown as SEQ ID NO.4-6. When the aldosterone sandwich method antibody mAb7 is used for detecting aldosterone standard antigens, the detection sensitivity is lower than 10 pg / mL, a clinical sample is detected through a magnetochemiluminescence method, the correlation with R clinical comparison is good in the sample range of 0-1000 pg / mL, and the aldosterone sandwich method antibody mAb7 has important significance in the field of diagnosis and treatment of primary hypertension and other aldosterone abnormality related diseases.

The present invention belongs to the field of molecular diagnosis of medical diseases and their treatment. More specifically, the present invention provides methods and means for detecting hypertension, more specifically essential primary hypertension, and even more specifically NOX5-dependent hypertension. The present invention also provides methods for treating hypertension, more specifically essential primary hypertension, and more specifically NOX5-dependent hypertension. The present invention also provides theragnostics combining therapy with diagnosis, more specifically, determining the level of NOX5 in a sample from a subject, and treating the subject with a NOX5 inhibitor or a compound that reduces the level of NOX5 if the NOX5 level exceeds a certain threshold. Furthermore, the present invention also provides theragnostics combining diagnosis with therapy, more specifically, determining the level of NOX5 (plasma) in a sample from a subject, and treating the subject with a NOX5 inhibitor or a compound that reverses the consequences of NOX5 activity if the determined NOX5 level exceeds a predetermined threshold. Finally, the present invention relates to animal models suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension.

The invention discloses an application of an autocrine Irisin probiotic B.Subtills-WB600-Irisin in preparation of a medicine for preventing / treating primary hypertension, and belongs to the field of biological medicines. The invention further discloses a preparation method of the autocrine Irisin probiotic B.Subtills-WB600-Irisin. According to the application disclosed by the invention, it is found for the first time that the probiotic B.Subtills-WB600-Irisin capable of automatically secreting Irisin protein simultaneously has the effect of preventing / treating primary hypertension, can effectively reduce systolic pressure of a rat with primary hypertension, and has no obvious influence on diastolic pressure. According to the invention, autocrine Irisin probiotics (B.Subtills-WB600-Irisin) are activated and then prepared into an oral preparation, in an SHR model, primary hypertension is prevented and treated by oral administration of the bacterial preparation (1 * 10 < 9 > CFU / day), and continuous blood pressure reduction (systolic pressure reduction gt, 20 mmHg) can be realized. The invention not only provides the first type of movement simulation probiotics for hypertension treatment, but also opens up a new path for microbial therapy of other metabolic diseases (such as diabetes and obesity), and has important clinical transformation and application.

The present disclosure provides a blood coagulation factor FXI / FXIa inhibitor for treating pulmonary hypertension and / or hypertension. Specifically, provided is a method for treating and / or preventing pulmonary hypertension in a patient receiving a conventional treatment by means of administering the FXI / FXIa inhibitor; and a method for treating and / or preventing hypertension in a patient with essential hypertension by means of administering the FXI / FXIa inhibitor.

The application discloses an immunogenic short peptide of angiotensin II receptor type 1 and application thereof, wherein the amino acid sequence of the immunogenic short peptide is shown as SEQ ID No. 1: AFHYE. An effective component of the immunogenic carrier vaccine is a coupling product of the immunogenic short peptide and a carrier. The application couples the immunogenic short peptide with a Qbeta carrier to obtain an effective component of the vaccine of the immunogenic peptide segment of angiotensin II receptor type 1. The effective component is used for preparing the immunogenic carrier vaccine for antihypertensive treatment of primary hypertension, can be used as a long-acting antihypertensive drug, and is helpful to improving the compliance of the primary hypertension patients in treatment, thereby achieving the purpose of effectively controlling blood pressure.

The invention provides a marker and a model for diagnosing primary aldosteronism and application of the marker and the model, and the marker and the model are used for diagnosing primary aldosteronism by analyzing primary aldosteronism samples and primary hypertension samples of a national multi-center queue in combination with univariate analysis and logistic regression analysis methods. According to the method, the primary aldosteronism marker is screened out, a decision tree algorithm is further utilized to construct a prediction model, the LC-MS / MS technology is combined with the prediction model, intelligent, rapid, simple and convenient prediction and diagnosis of the primary aldosteronism are achieved, and clinical requirements are met.

The disclosure relates to a combination of biomarkers comprising at least: (i-a) one biomarker selected in each of the following group of biomarkers: Patient's age, Plasma steroids, and Urinary steroids, and at least one biomarker selected in at least one of the group of biomarkers: O-methylated catecholamines, Small metabolites, and miRNA; or (i-b) one biomarker selected in each of the following group of biomarkers: Plasma steroids, Urinary steroids, and Small metabolites, and at least one biomarker selected in at least one of the group of biomarkers: Patient's age, O-methylated catecholamines, and miRNA. The combinations of biomarkers may be used for stratifying a hypertensive patient among different hypertensive diseases comprising Endocrine Hypertension (EHT), Primary Aldosteronism (PA), Pheochromocytoma / Functional Paraganglioma (PPGL), Cushing's Syndrome (CS), and Primary Hypertension (PHT).

The invention discloses application of isoliquiritigenin in preparation of a product for treating primary hypertension, and belongs to the technical field of medicines. Experimental verification finds that the isoliquiritigenin improves primary hypertension vascular remodeling by reducing proliferation and migration capabilities of medial vascular smooth muscle cells and promoting the vascular smooth muscle cells to be converted from a synthetic type to a contractile type at the same time. The invention provides a new medicine for treating primary hypertension, and meanwhile, the new application of the isoliquiritigenin provides a new way for comprehensively developing medicinal resources of the isoliquiritigenin.

The invention discloses a losartan potassium pharmaceutical composition as well as a preparation method and application thereof. The losartan potassium pharmaceutical composition comprises a eutectic compound formed by losartan potassium and arginine and polyethylene glycol with the molecular weight of 4000. Through the synergistic effect of a co-crystallization technology and specific auxiliary materials, the solubility and stability of losartan potassium are remarkably improved, and the dissolution rate of losartan potassium in a hydrochloric acid medium with the pH value of 1.2 for 15 min reaches up to 85% or above and is far superior to that of commercially available common tablets. Animal experiments show that the relative bioavailability of the pharmaceutical composition can reach more than 200% of that of a commercially available reference preparation, so that low-dose efficient treatment is realized, and adverse reactions are reduced. The composition has excellent stability under high-temperature and high-humidity conditions, is suitable for preparing medicines for treating primary hypertension and related cardiovascular diseases, and has important clinical value.